Hansa Biopharma AB (HNSA) - Total Assets
Based on the latest financial reports, Hansa Biopharma AB (HNSA) holds total assets worth Skr837.27 Million SEK (≈ $90.10 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore HNSA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Hansa Biopharma AB - Total Assets Trend (2008–2024)
This chart illustrates how Hansa Biopharma AB's total assets have evolved over time, based on quarterly financial data. See HNSA net assets for net asset value and shareholders' equity analysis.
Hansa Biopharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Hansa Biopharma AB's total assets of Skr837.27 Million consist of 73.1% current assets and 26.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 50.6% |
| Accounts Receivable | Skr146.33 Million | 18.3% |
| Inventory | Skr2.61 Million | 0.3% |
| Property, Plant & Equipment | Skr17.88 Million | 2.2% |
| Intangible Assets | Skr197.33 Million | 24.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Hansa Biopharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Hansa Biopharma AB worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hansa Biopharma AB's current assets represent 73.1% of total assets in 2024, an increase from 17.2% in 2008.
- Cash Position: Cash and equivalents constituted 50.6% of total assets in 2024, up from 13.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 24.7% of total assets.
Hansa Biopharma AB Competitors by Total Assets
Key competitors of Hansa Biopharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Hansa Biopharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 3.05 | 12.94 |
| Quick Ratio | 1.36 | 3.04 | 12.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr156.84 Million | Skr564.72 Million | Skr1.37 Billion |
Hansa Biopharma AB - Advanced Valuation Insights
This section examines the relationship between Hansa Biopharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.05 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | Skr800.64 Million |
| Market Capitalization | $356.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hansa Biopharma AB's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hansa Biopharma AB's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hansa Biopharma AB (2008–2024)
The table below shows the annual total assets of Hansa Biopharma AB from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr800.64 Million ≈ $86.16 Million |
-21.35% |
| 2023-12-31 | Skr1.02 Billion ≈ $109.56 Million |
-39.67% |
| 2022-12-31 | Skr1.69 Billion ≈ $181.59 Million |
+66.61% |
| 2021-12-31 | Skr1.01 Billion ≈ $108.99 Million |
-29.40% |
| 2020-12-31 | Skr1.43 Billion ≈ $154.37 Million |
+115.96% |
| 2019-12-31 | Skr664.24 Million ≈ $71.48 Million |
-29.70% |
| 2018-12-31 | Skr944.82 Million ≈ $101.68 Million |
+38.86% |
| 2017-12-31 | Skr680.41 Million ≈ $73.22 Million |
+119.01% |
| 2016-12-31 | Skr310.67 Million ≈ $33.43 Million |
+38.64% |
| 2015-12-31 | Skr224.09 Million ≈ $24.12 Million |
+312.60% |
| 2014-12-31 | Skr54.31 Million ≈ $5.84 Million |
+6.96% |
| 2013-12-31 | Skr50.78 Million ≈ $5.46 Million |
-22.83% |
| 2012-12-31 | Skr65.80 Million ≈ $7.08 Million |
+60.89% |
| 2011-12-31 | Skr40.90 Million ≈ $4.40 Million |
+8.19% |
| 2010-12-31 | Skr37.80 Million ≈ $4.07 Million |
-0.91% |
| 2009-12-31 | Skr38.15 Million ≈ $4.11 Million |
-14.98% |
| 2008-12-31 | Skr44.87 Million ≈ $4.83 Million |
-- |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more